ArticleAmerican journal of translational research2026
Worse outcomes and distinct clinical features in infants with necrotizing enterocolitis and congenital heart disease.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to compare the clinical characteristics and outcomes in infants with necrotizing enterocolitis (NEC) with and without congenital heart disease (CHD) and to further evaluate the impact of isolated patent ductus arteriosus (PDA) on NEC severity.
methodsA retrospective cohort study involving 165 infants diagnosed with NEC at our center from January 2015 to April 2025 was conducted. Patients were stratified into two groups: those with CHD (n=75) and those without CHD (n=90). Demographic, clinical, laboratory, and outcome data were collected. Intergroup comparisons were performed using nonparametric and chi-square tests. Univariate and multivariate logistic regression analyses were employed to identify factors associated with severe outcomes.
resultsCompared with infants without CHD, infants with CHD had significantly younger gestational ages (median [IQR]: 30.2 [28.5-32.1] vs. 32.5 [31.0-34.0] weeks, P<0.01) and birth weights (1250 [980-1500] vs. 1580 [1350-1820] grams, P<0.01), longer durations of respiratory support (15 [10-25] vs. 8 [5-12] days, P<0.01), longer hospital stays (45 [35-60] vs. 32 [25-40] days, P<0.01), and greater mortality (28.0% vs. 11.1%, P<0.01). Notably, the severity of NEC (Bell's stage II/III) did not differ significantly between infants with isolated PDA and those with other forms of CHD (65% vs. 68%, P=0.82). Multivariate analysis revealed lower serum albumin levels and thrombocytopenia at onset as potential early indicators for adverse outcomes in the CHD group.
conclusionsNEC in infants with CHD is associated with a more severe clinical course and poorer prognosis. Compared with other CHD types, the presence of isolated PDA does not confer an additional risk for more severe NEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.